NDC 65162-698-39 - Gabapentin
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 65162-698
- Requested NDC
- 65162-698-39
- Package NDCs from labels
- 65162-698-90, 65162-698-39, 65162-698-54
- Manufacturer
- Amneal Pharmaceuticals LLC | Amneal Pharmaceuticals, LLC
- Effective date
- 2025-05-13
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Gabapentin - Amneal Pharmaceuticals LLC | Amneal Pharmaceuticals, LLC | Amneal Pharmaceuticals LLC | Amneal Pharmaceuticals, LLC | 2025-05-13 | HUMAN PRESCRIPTION DRUG LABEL |
| Gabapentin - ATLANTIC BIOLOGICALS CORP. | ATLANTIC BIOLOGICALS CORP. | 2023-04-12 | HUMAN PRESCRIPTION DRUG LABEL |
FDA-Initiated Inactive NDC Indexing#
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 65162-698-39 | Gabapentin | 5 mL in 1 CUP, UNIT-DOSE | SOLUTION | 5 | 28 | |
| 65162-698-54 | Gabapentin | 50 in 1 CARTON | SOLUTION | 50 | 28 | |
| 65162-698-90 | Gabapentin | 473 mL in 1 BOTTLE | SOLUTION | 473 | 28 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 65162-698-90 | ML - Milliliter | 65162-698 | 781d1576-35f2-4340-9bb7-8435d1507cd5 | 1 | 2012-07-24 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| GABAPENTIN | ACTIVE INGREDIENT | 6CW7F3G59X | GABAPENTIN SOLUTION [AMNEAL PHARMACEUTICALS OF NEW YORK, LLC] | 7 | |
| GABAPENTIN | ACTIVE MOIETY | 6CW7F3G59X | GABAPENTIN SOLUTION [AMNEAL PHARMACEUTICALS OF NEW YORK, LLC] | 7 | |
| ACESULFAME POTASSIUM | INACTIVE INGREDIENT | 23OV73Q5G9 | GABAPENTIN SOLUTION [AMNEAL PHARMACEUTICALS OF NEW YORK, LLC] | 7 | |
| CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED FORM | INACTIVE INGREDIENT | K679OBS311 | GABAPENTIN SOLUTION [AMNEAL PHARMACEUTICALS OF NEW YORK, LLC] | 7 | |
| HYDROCHLORIC ACID | INACTIVE INGREDIENT | QTT17582CB | GABAPENTIN SOLUTION [AMNEAL PHARMACEUTICALS OF NEW YORK, LLC] | 7 | |
| POTASSIUM SORBATE | INACTIVE INGREDIENT | 1VPU26JZZ4 | GABAPENTIN SOLUTION [AMNEAL PHARMACEUTICALS OF NEW YORK, LLC] | 7 | |
| SODIUM HYDROXIDE | INACTIVE INGREDIENT | 55X04QC32I | GABAPENTIN SOLUTION [AMNEAL PHARMACEUTICALS OF NEW YORK, LLC] | 7 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Chemstat | GLYCERINUM, TARAXACUM OFFICINALE, PHYTOLACCA DECANDRA, ARSENICUM ALBUM, NITRICUM ACIDUM, NUX VOMICA, PETROLEUM, PHOSPHORICUM ACIDUM, PHOSPHORUS, ACETYLSALICYLICUM ACIDUM, GLONOINUM, INSULINUM (HUMAN), LITHIUM CARBONICUM, THYROIDINUM (SUIS), ACETICUM ACIDUM, BENZOICUM ACIDUM, BENZYL ALCOHOL, BORICUM ACIDUM, CHLORINUM, CORTISONE ACETICUM, EUGENOL, FOLLICULINUM, ISOPROPYL PALMITATE, LACTICUM ACIDUM, PETROLEUM JELLY, PHENYL BUTAZONE, PLUMBUM METALLICUM, POTASSIUM SORBATE, RESORCINUM, SALICYLICUM ACIDUM, | Energique, Inc. | 2831d28e-9cf1-4a72-9c6c-bb014d059558 | 2026-05-06 | Warnings | 1VPU26JZZ4 |
| Gabapentin | GABAPENTIN | Major Pharmaceuticals | 152adf1d-ec0c-4561-bf80-e4c7da158723 | 2026-05-04 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Major Pharmaceuticals | 999f3685-2eac-467e-bed2-1d0c36aaf0ed | 2026-05-04 | Warnings, Adverse reactions | 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | Preferred Pharmaceuticals Inc. | 180b99a5-7d3d-4ee5-a0cc-1ae0ede646ee | 2026-05-04 | Warnings, Adverse reactions | 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | Preferred Pharmaceuticals Inc. | 35da078b-0da0-4757-a6c4-a9144c37e8e1 | 2026-05-01 | Warnings, Adverse reactions | 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | Preferred Pharmaceuticals Inc. | 38119f2e-33b3-4c3c-99b7-9335d8d280d4 | 2026-05-01 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | St. Mary's Medical Park Pharmacy | b8b7e045-a7fe-8539-e053-2a95a90a40f8 | 2026-05-01 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | St Mary's Medical Park Pharmacy | de990f96-96bc-406d-e053-2995a90abebb | 2026-05-01 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Bryant Ranch Prepack | 4cb26d6e-7963-4fe5-903e-ab5180545066 | 2026-05-01 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Preferred Pharmaceuticals Inc. | 100ff86c-56a8-4770-9db3-b9bc6b1bd2f7 | 2026-04-30 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | PD-Rx Pharmaceuticals, Inc. | d22ed424-f365-44ca-8ef9-a08255a90ae8 | 2026-04-29 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Preferred Pharmaceuticals Inc. | e3429322-c442-4146-bb68-bcc3a8d01552 | 2026-04-29 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Preferred Pharmaceuticals Inc. | 2625c0ef-5295-41de-9e81-88001a6cbecc | 2026-04-29 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Preferred Pharmaceuticals Inc. | 6ecf5114-2ddc-4025-a36d-1884702dc22a | 2026-04-29 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Preferred Pharmaceuticals Inc. | f396ec70-826d-45c6-a27c-343c2fac878c | 2026-04-29 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Preferred Pharmaceuticals, Inc. | 41dcc917-68d1-49f0-8223-44c21ca259ef | 2026-04-29 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Coupler LLC | 5073abda-321f-29d1-e063-6394a90a59ac | 2026-04-27 | Warnings, Adverse reactions | 6CW7F3G59X |
| REFRESH TEARS PF | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN | Allergan, Inc. | 9e1cba7b-84ed-47f3-b19a-121992834350 | 2026-04-24 | Warnings | K679OBS311 |
| Gabapentin | GABAPENTIN | BluePoint Laboratories | 3368bf70-d466-4765-b2b7-7fe967a8c2b7 | 2026-04-24 | Warnings, Adverse reactions | 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | Coupler LLC | 500ee820-0378-6fc9-e063-6394a90a109c | 2026-04-24 | Warnings, Adverse reactions | 6CW7F3G59X |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.